# Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

> **NCT03694392** · — · COMPLETED · sponsor: **Kaiser Permanente** · enrollment: 2776278 (actual)

## Conditions studied

- Influenza
- Pneumonia
- Lower Respiratory Tract Infection
- Acute Myocardial Infarction
- Congestive Heart Failure
- Stroke

## Interventions

- **BIOLOGICAL:** Flublok Quadrivalent
- **BIOLOGICAL:** Standard Dose Inactivated Influenza Vaccine (SD-IIV)

## Key facts

- **NCT ID:** NCT03694392
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-16
- **Primary completion:** 2021-04-09
- **Final completion:** 2022-12-31
- **Target enrollment:** 2776278 (ACTUAL)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694392, "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03694392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*